Does the media favor MDLN or GEHC?

In the previous week, Medline had 6 more articles in the media than GE HealthCare Technologies. MarketBeat recorded 16 mentions for Medline and 10 mentions for GE HealthCare Technologies. GE HealthCare Technologies' average media sentiment score of 1.04 beat Medline's score of 0.18 indicating that GE HealthCare Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Medline 2 Very Positive mention(s) 0 Positive mention(s) 14 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral GE HealthCare Technologies 4 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend MDLN or PHG?

Medline currently has a consensus target price of $50.54, indicating a potential upside of 40.21%. Given Medline's stronger consensus rating and higher probable upside, equities research analysts clearly believe Medline is more favorable than Koninklijke Philips. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Medline 1 Sell rating(s) 5 Hold rating(s) 22 Buy rating(s) 1 Strong Buy rating(s) 2.79 Koninklijke Philips 0 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media favor MDLN or PHG?

In the previous week, Medline had 15 more articles in the media than Koninklijke Philips. MarketBeat recorded 16 mentions for Medline and 1 mentions for Koninklijke Philips. Koninklijke Philips' average media sentiment score of 0.33 beat Medline's score of 0.18 indicating that Koninklijke Philips is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Medline 2 Very Positive mention(s) 0 Positive mention(s) 14 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Koninklijke Philips 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings and valuation, ZBH or MDLN?

Medline has higher revenue and earnings than Zimmer Biomet. Zimmer Biomet is trading at a lower price-to-earnings ratio than Medline, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zimmer Biomet $8.23B 2.13 $705.20M $3.85 23.50 Medline $28.43B 1.67 $1.16B $0.32 112.64

Does the media refer more to ZBH or MDLN?

In the previous week, Medline had 8 more articles in the media than Zimmer Biomet. MarketBeat recorded 16 mentions for Medline and 8 mentions for Zimmer Biomet. Zimmer Biomet's average media sentiment score of 1.16 beat Medline's score of 0.18 indicating that Zimmer Biomet is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zimmer Biomet 6 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Medline 2 Very Positive mention(s) 0 Positive mention(s) 14 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings and valuation, SOLV or MDLN?

Solventum has higher earnings, but lower revenue than Medline. Solventum is trading at a lower price-to-earnings ratio than Medline, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Solventum $8.33B 1.57 $1.56B $8.16 9.26 Medline $28.43B 1.67 $1.16B $0.32 112.64

Is SOLV or MDLN more profitable?

Solventum has a net margin of 17.33% compared to Medline's net margin of 0.00%. Solventum's return on equity of 23.51% beat Medline's return on equity. Company Net Margins Return on Equity Return on Assets Solventum 17.33% 23.51% 7.63% Medline N/A N/A N/A

Does the media prefer SOLV or MDLN?

In the previous week, Medline had 13 more articles in the media than Solventum. MarketBeat recorded 16 mentions for Medline and 3 mentions for Solventum. Solventum's average media sentiment score of 0.25 beat Medline's score of 0.18 indicating that Solventum is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Solventum 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Medline 2 Very Positive mention(s) 0 Positive mention(s) 14 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation & earnings, MDLN or SNN?

Medline has higher revenue and earnings than Smith & Nephew SNATS. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Medline $28.43B 1.67 $1.16B $0.32 112.64 Smith & Nephew SNATS $6.16B 2.09 $625M N/A N/A

Is MDLN or SNN more profitable?

Company Net Margins Return on Equity Return on Assets Medline N/A N/A N/A Smith & Nephew SNATS N/A N/A N/A

Medline (MDLN) Competitors

$36.04 +0.75 (+2.11%)

Closing price 03:59 PM Eastern

Extended Trading

$36.54 +0.50 (+1.39%)

As of 07:02 PM Eastern

Compare

MDLN vs. GEHC, PHG, ZBH, SOLV, and SNN

Should you buy Medline stock or one of its competitors? MarketBeat compares Medline with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Medline include GE HealthCare Technologies (GEHC), Koninklijke Philips (PHG), Zimmer Biomet (ZBH), Solventum (SOLV), and Smith & Nephew SNATS (SNN). These companies are all part of the "medical equipment" industry.

How does Medline compare to GE HealthCare Technologies?

Medline (NASDAQ:MDLN) and GE HealthCare Technologies (NASDAQ:GEHC) are both large-cap medical equipment companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, profitability, analyst recommendations, risk, valuation and dividends.

Medline presently has a consensus price target of $50.54, indicating a potential upside of 40.21%. GE HealthCare Technologies has a consensus price target of $80.20, indicating a potential upside of 23.40%. Given Medline's stronger consensus rating and higher possible upside, equities analysts clearly believe Medline is more favorable than GE HealthCare Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medline	1 Sell rating(s)	5 Hold rating(s)	22 Buy rating(s)	1 Strong Buy rating(s)	2.79
GE HealthCare Technologies	0 Sell rating(s)	9 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.53

GE HealthCare Technologies has a net margin of 9.10% compared to Medline's net margin of 0.00%. GE HealthCare Technologies' return on equity of 20.46% beat Medline's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medline	N/A	N/A	N/A
GE HealthCare Technologies	9.10%	20.46%	5.73%

82.1% of GE HealthCare Technologies shares are owned by institutional investors. 0.8% of Medline shares are owned by insiders. Comparatively, 0.4% of GE HealthCare Technologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

GE HealthCare Technologies has lower revenue, but higher earnings than Medline. GE HealthCare Technologies is trading at a lower price-to-earnings ratio than Medline, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medline	$28.43B	1.67	$1.16B	$0.32	112.64
GE HealthCare Technologies	$20.98B	1.41	$2.08B	$4.18	15.55

In the previous week, Medline had 6 more articles in the media than GE HealthCare Technologies. MarketBeat recorded 16 mentions for Medline and 10 mentions for GE HealthCare Technologies. GE HealthCare Technologies' average media sentiment score of 1.04 beat Medline's score of 0.18 indicating that GE HealthCare Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Medline	2 Very Positive mention(s)	0 Positive mention(s)	14 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
GE HealthCare Technologies	4 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Medline beats GE HealthCare Technologies on 9 of the 16 factors compared between the two stocks.

How does Medline compare to Koninklijke Philips?

Medline (NASDAQ:MDLN) and Koninklijke Philips (NYSE:PHG) are both large-cap medical equipment companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations, media sentiment and risk.

Medline currently has a consensus target price of $50.54, indicating a potential upside of 40.21%. Given Medline's stronger consensus rating and higher probable upside, equities research analysts clearly believe Medline is more favorable than Koninklijke Philips.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medline	1 Sell rating(s)	5 Hold rating(s)	22 Buy rating(s)	1 Strong Buy rating(s)	2.79
Koninklijke Philips	0 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Medline has higher revenue and earnings than Koninklijke Philips. Koninklijke Philips is trading at a lower price-to-earnings ratio than Medline, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medline	$28.43B	1.67	$1.16B	$0.32	112.64
Koninklijke Philips	$17.64B	1.49	$1.01B	$1.17	22.84

Koninklijke Philips has a net margin of 5.49% compared to Medline's net margin of 0.00%. Koninklijke Philips' return on equity of 13.51% beat Medline's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medline	N/A	N/A	N/A
Koninklijke Philips	5.49%	13.51%	5.48%

13.7% of Koninklijke Philips shares are owned by institutional investors. 0.8% of Medline shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Medline had 15 more articles in the media than Koninklijke Philips. MarketBeat recorded 16 mentions for Medline and 1 mentions for Koninklijke Philips. Koninklijke Philips' average media sentiment score of 0.33 beat Medline's score of 0.18 indicating that Koninklijke Philips is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Medline	2 Very Positive mention(s)	0 Positive mention(s)	14 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Koninklijke Philips	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Medline beats Koninklijke Philips on 10 of the 16 factors compared between the two stocks.

How does Medline compare to Zimmer Biomet?

Zimmer Biomet (NYSE:ZBH) and Medline (NASDAQ:MDLN) are both large-cap medical equipment companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation and institutional ownership.

Zimmer Biomet currently has a consensus target price of $102.70, indicating a potential upside of 13.53%. Medline has a consensus target price of $50.54, indicating a potential upside of 40.21%. Given Medline's stronger consensus rating and higher probable upside, analysts clearly believe Medline is more favorable than Zimmer Biomet.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zimmer Biomet	3 Sell rating(s)	12 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.26
Medline	1 Sell rating(s)	5 Hold rating(s)	22 Buy rating(s)	1 Strong Buy rating(s)	2.79

Zimmer Biomet has a net margin of 9.05% compared to Medline's net margin of 0.00%. Zimmer Biomet's return on equity of 13.24% beat Medline's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zimmer Biomet	9.05%	13.24%	7.28%
Medline	N/A	N/A	N/A

88.9% of Zimmer Biomet shares are owned by institutional investors. 1.3% of Zimmer Biomet shares are owned by insiders. Comparatively, 0.8% of Medline shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Medline had 8 more articles in the media than Zimmer Biomet. MarketBeat recorded 16 mentions for Medline and 8 mentions for Zimmer Biomet. Zimmer Biomet's average media sentiment score of 1.16 beat Medline's score of 0.18 indicating that Zimmer Biomet is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zimmer Biomet	6 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Medline	2 Very Positive mention(s)	0 Positive mention(s)	14 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Medline has higher revenue and earnings than Zimmer Biomet. Zimmer Biomet is trading at a lower price-to-earnings ratio than Medline, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zimmer Biomet	$8.23B	2.13	$705.20M	$3.85	23.50
Medline	$28.43B	1.67	$1.16B	$0.32	112.64

Summary

Zimmer Biomet beats Medline on 8 of the 15 factors compared between the two stocks.

How does Medline compare to Solventum?

Solventum (NYSE:SOLV) and Medline (NASDAQ:MDLN) are both large-cap medical equipment companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, earnings, media sentiment, profitability, institutional ownership and dividends.

Solventum has a net margin of 17.33% compared to Medline's net margin of 0.00%. Solventum's return on equity of 23.51% beat Medline's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solventum	17.33%	23.51%	7.63%
Medline	N/A	N/A	N/A

Solventum has higher earnings, but lower revenue than Medline. Solventum is trading at a lower price-to-earnings ratio than Medline, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solventum	$8.33B	1.57	$1.56B	$8.16	9.26
Medline	$28.43B	1.67	$1.16B	$0.32	112.64

In the previous week, Medline had 13 more articles in the media than Solventum. MarketBeat recorded 16 mentions for Medline and 3 mentions for Solventum. Solventum's average media sentiment score of 0.25 beat Medline's score of 0.18 indicating that Solventum is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Solventum	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Medline	2 Very Positive mention(s)	0 Positive mention(s)	14 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Solventum currently has a consensus price target of $84.25, indicating a potential upside of 11.53%. Medline has a consensus price target of $50.54, indicating a potential upside of 40.21%. Given Medline's stronger consensus rating and higher possible upside, analysts plainly believe Medline is more favorable than Solventum.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solventum	1 Sell rating(s)	5 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.50
Medline	1 Sell rating(s)	5 Hold rating(s)	22 Buy rating(s)	1 Strong Buy rating(s)	2.79

Summary

Medline beats Solventum on 8 of the 14 factors compared between the two stocks.

How does Medline compare to Smith & Nephew SNATS?

Medline (NASDAQ:MDLN) and Smith & Nephew SNATS (NYSE:SNN) are both large-cap medical equipment companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, risk, profitability, media sentiment, analyst recommendations, institutional ownership and valuation.

25.6% of Smith & Nephew SNATS shares are owned by institutional investors. 0.8% of Medline shares are owned by company insiders. Comparatively, 1.0% of Smith & Nephew SNATS shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Company	Net Margins	Return on Equity	Return on Assets
Medline	N/A	N/A	N/A
Smith & Nephew SNATS	N/A	N/A	N/A

Medline has higher revenue and earnings than Smith & Nephew SNATS.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medline	$28.43B	1.67	$1.16B	$0.32	112.64
Smith & Nephew SNATS	$6.16B	2.09	$625M	N/A	N/A

In the previous week, Medline had 16 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 16 mentions for Medline and 0 mentions for Smith & Nephew SNATS. Medline's average media sentiment score of 0.18 beat Smith & Nephew SNATS's score of 0.00 indicating that Medline is being referred to more favorably in the media.

Company	Overall Sentiment
Medline	Neutral
Smith & Nephew SNATS	Neutral

Medline currently has a consensus target price of $50.54, indicating a potential upside of 40.21%. Smith & Nephew SNATS has a consensus target price of $30.93, indicating a potential upside of 2.13%. Given Medline's stronger consensus rating and higher probable upside, analysts plainly believe Medline is more favorable than Smith & Nephew SNATS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medline	1 Sell rating(s)	5 Hold rating(s)	22 Buy rating(s)	1 Strong Buy rating(s)	2.79
Smith & Nephew SNATS	0 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.17

Summary

Medline beats Smith & Nephew SNATS on 8 of the 11 factors compared between the two stocks.

Get Medline News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MDLN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MDLN vs. The Competition

Export

Metric	Medline	Surgical, Medical, And Dental Instruments And Supplies Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$47.35B	$2.73B	$4.30B	$12.24B
Dividend Yield	N/A	N/A	10.93%	5.82%
P/E Ratio	112.64	13.58	22.06	23.98
Price / Sales	1.67	68.14	113.55	120.62
Price / Cash	20.46	7.81	40.77	54.51
Price / Book	2.46	5.95	15.92	6.41
Net Income	$1.16B	$7.39M	$115.37M	$337.14M
7 Day Performance	-1.03%	-3.18%	-1.28%	-0.48%
1 Month Performance	-2.61%	-8.48%	-2.41%	0.49%
1 Year Performance	N/A	11.11%	11.29%	28.16%

Medline Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MDLN Medline	4.1086 of 5 stars	$36.05 +2.1%	$50.54 +40.2%	N/A	$47.35B	$28.43B	112.64	45,000
GEHC GE HealthCare Technologies	4.9116 of 5 stars	$61.53 +0.6%	$80.21 +30.4%	-10.5%	$27.95B	$20.98B	14.70	54,000	Positive News Analyst Forecast
PHG Koninklijke Philips	2.6104 of 5 stars	$26.67 +1.7%	N/A	+17.4%	$25.61B	$17.64B	22.79	65,340
ZBH Zimmer Biomet	4.6338 of 5 stars	$88.51 +1.6%	$102.70 +16.0%	-4.2%	$17.13B	$8.23B	22.99	17,000	Positive News
SOLV Solventum	3.3568 of 5 stars	$74.81 +0.3%	$84.25 +12.6%	+1.3%	$12.90B	$8.33B	9.13	20,000

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MDLN) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Medline (MDLN) Competitors

MDLN vs. GEHC, PHG, ZBH, SOLV, and SNN

How does Medline compare to GE HealthCare Technologies?

Summary

How does Medline compare to Koninklijke Philips?

Summary

How does Medline compare to Zimmer Biomet?

Summary

How does Medline compare to Solventum?

Summary

How does Medline compare to Smith & Nephew SNATS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDLN vs. The Competition

Medline Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Medline (MDLN) Competitors

MDLN vs. GEHC, PHG, ZBH, SOLV, and SNN

How does Medline compare to GE HealthCare Technologies?

Do analysts prefer MDLN or GEHC?

Is MDLN or GEHC more profitable?

Do institutionals and insiders believe in MDLN or GEHC?

Which has preferable valuation & earnings, MDLN or GEHC?

Does the media favor MDLN or GEHC?

Summary

How does Medline compare to Koninklijke Philips?

Do analysts recommend MDLN or PHG?

Which has better valuation and earnings, MDLN or PHG?

Is MDLN or PHG more profitable?

Do institutionals and insiders have more ownership in MDLN or PHG?

Does the media favor MDLN or PHG?

Summary

How does Medline compare to Zimmer Biomet?

Do analysts rate ZBH or MDLN?

Is ZBH or MDLN more profitable?

Do institutionals and insiders believe in ZBH or MDLN?

Does the media refer more to ZBH or MDLN?

Which has better earnings and valuation, ZBH or MDLN?

Summary

How does Medline compare to Solventum?

Is SOLV or MDLN more profitable?

Which has preferable earnings and valuation, SOLV or MDLN?

Does the media prefer SOLV or MDLN?

Do analysts prefer SOLV or MDLN?

Summary

How does Medline compare to Smith & Nephew SNATS?

Do institutionals & insiders have more ownership in MDLN or SNN?

Is MDLN or SNN more profitable?

Which has better valuation & earnings, MDLN or SNN?

Does the media refer more to MDLN or SNN?

Do analysts recommend MDLN or SNN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDLN vs. The Competition

Medline Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools